BioCentury | Jun 20, 2020
Translation in Brief

CAR Ts against senescent cells; plus NIH program for ALS, sex-dependent COVID-19 immune responses and more

...liver fibrosis therapy Memorial Sloan Kettering Cancer Center researchers have generated CAR T cells against PLAUR...
...high PLAUR expression levels in fibrotic liver and atherosclerotic plaque patient samples and showed that anti-PLAUR...
...small molecules, may conduct proof-of-concept animal studies. Targets IL-15 - Interleukin-15 PLAUR (uPAR) (suPAR) - Plasminogen activator urokinase receptor...
BioCentury | Nov 19, 2019

AGR2 and LYPD3 as breast cancer targets

...seeking partners for clinical development. TARGET/MARKER/PATHWAY: Anterior gradient 2, protein disulphide isomerase family member (AGR2); Ly6/PLAUR...
...of Medicine, Durham, N.C. email: donald.mcdonnell@duke.edu Claire Quang Duke University Anterior gradient 2, protein disulphide isomerase family member (AGR2) Ly6/PLAUR...
BioCentury | Aug 16, 2018
Translation in Brief

Selective hearing

...calbindin 1 (CALB1) were selectively expressed in type Ia and type Ib SGNs, respectively, while Ly6/PLAUR...
BioCentury | Jan 21, 2016
Finance

Italy's velocity factor

...at high risk of relapse Pier Paolo Di Fiore; IEO 2004 Cancer Plasminogen activator urokinase receptor (PLAUR; uPAR; suPAR...
BioCentury | Aug 10, 2015
Company News

Cancer Research UK, Monopar Therapeutics deal

...by the product. HuATN-658 is a human mAb targeting plasminogen activator urokinase receptor ( PLAUR ; uPAR ; suPAR...
BioCentury | Mar 7, 2013
Distillery Therapeutics

Indication: Cancer

...status Publication and contact information Cancer Breast cancer Plasminogen activator urokinase receptor (PLAUR; uPAR; suPAR) Mouse studies suggest anti-uPAR...
...treat aggressive breast cancer. In a mouse xenograft model for triple-negative breast cancer, two different anti-uPAR...
...a clinical trial. SciBX 6(9); doi:10.1038/scibx.2013.211 Published online March 7, 2013 Patent applications filed covering uPAR-binding...
BioCentury | Jul 16, 2012
Company News

Tactic Pharma, Wilson Therapeutics deal

...also has ATN-658 , a preclinical humanized mAb against plasminogen activator urokinase receptor ( PLAUR ; uPAR ; suPAR...
BioCentury | Aug 18, 2011
Distillery Therapeutics

Indication: Renal disease

...Licensing status Publication and contact information Renal disease End-stage renal disease (ESRD) Plasminogen activator urokinase receptor (PLAUR; uPAR; suPAR...
...uPAR; suPAR) A study in mice and in patient samples suggests decreasing serum levels of uPAR...
...uPAR levels than serum from healthy controls. In a mouse model of FSGS, mAbs against uPAR...
BioCentury | May 31, 2010
Finance

Performance Counts

...plasminogen activator (uPA), a member of the serine protease family, together with its receptor ( uPAR...
BioCentury | Mar 19, 2009
Distillery Therapeutics

Indication: Cancer

...pathway Summary Licensing status Publication and contact information Cancer Cancer Plasminogen activator, urokinase receptor (PLAUR; UPAR...
...treat cancer. In vitro, plasmin cleaved UPAR. In mice transplanted with bone marrow cells, a UPAR-neutralizing...
...in preclinical testing to treat cancer. Wilex AG's Mesupron and WX-UK1, serine protease inhibitors targeting UPAR...
Items per page:
1 - 10 of 21